Focused On-demand Library for Cytoplasmic dynein 2 intermediate chain 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8WVS4

UPID:

DC2I1_HUMAN

Alternative names:

Dynein 2 intermediate chain 1; WD repeat-containing protein 60

Alternative UPACC:

Q8WVS4; Q9NW58

Background:

Cytoplasmic dynein 2 intermediate chain 1, also known as Dynein 2 intermediate chain 1 and WD repeat-containing protein 60, is a crucial component of the cytoplasmic dynein 2 complex. This protein complex is essential for the movement of cargos along microtubules within cilia and flagella, working in harmony with the intraflagellar transport system. It plays a significant role in retrograde ciliary protein trafficking and is vital for maintaining a functional transition zone.

Therapeutic significance:

Short-rib thoracic dysplasia 8 with or without polydactyly, a condition marked by skeletal abnormalities and potential non-skeletal involvement, is caused by variants affecting this gene. Understanding the role of Cytoplasmic dynein 2 intermediate chain 1 could open doors to potential therapeutic strategies for this spectrum of diseases.